

**ACTION:** Notice of public workshop.

**SUMMARY:** The Food and Drug Administration (FDA), Office of Regulatory Affairs (ORA), Southwest Region (SWR), Dallas District Office (DALDO), in collaboration with the FDA Medical Device Industry Coalition (FMDIC) is announcing a public workshop entitled "Quality Systems Educational Forum: Production and Process Controls." This public workshop is intended to provide information about FDA's Medical Device Quality Systems Regulation (QSR) to the regulated industry, particularly small businesses.

**Date and Time:** The public workshop will be held on April 23, 2004, from 8 a.m. to 5 p.m.

**Location:** The public workshop will be held at the Crowne Plaza Dallas Market Center Hotel, 7050 I-35 Stemmons Freeway, Dallas, TX 75247. Directions to the facility are available at the FMDIC Web site at <http://www.fmdic.org>.<sup>1</sup>

**Contact Person:** David Arvelo or Sue Thomason, Food and Drug Administration, 4040 North Central Expressway, suite 900, Dallas, TX 75204, 214-253-4952 or 214-253-4951, FAX: 214-253-4970, e-mail [oraswrsbr@ora.fda.gov](mailto:oraswrsbr@ora.fda.gov).

**Registration:** FMDIC has a \$150 early registration fee. Early registration begins on February 1 and ends March 26, 2004. Registration is \$175 from March 27 to April 9, 2004. To register online, please visit <http://www.fmdic.org/>. As an alternative, you may send registration information including name, title, firm name, address, telephone and fax numbers, and e-mail along with a check or money order for the appropriate amount payable to the FMDIC to Dr. William Hyman, Texas A&M University, Department of Biomedical Engineering, 3120 Tamu, College Station, TX 75843-3120. Course space will be filled in order of receipt of registration *with appropriate fees*. Seats are limited, please submit registration form as soon as possible. Those accepted into the course will receive confirmation. Registration will close after the course is filled. Registration at the site will be done on a space available basis on the day of the public workshop beginning at 8 a.m. The cost of registration at the site is \$175 payable to the FMDIC. The registration fee will be used to offset expenses of hosting the conference, including meals, refreshments, meeting rooms, and materials.

If you need special accommodations due to a disability, please contact David Arvelo or Sue Thomason at least 7 days in advance.

**Transcripts:** Transcripts of the public workshop will *not* be available due to the format of this workshop. Course handouts may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days after the public workshop at a cost of 10 cents per page.

**SUPPLEMENTARY INFORMATION:** The workshop is being held in response to the interest in the topics discussed from small medical device manufacturers in the Dallas District area. FMDIC and FDA present this workshop to help achieve objectives set forth in section 406 of the Food and Drug Administration Modernization Act of 1997 (21 U.S.C. 393), which include working closely with stakeholders and maximizing the availability and clarity of information to stakeholders and the public. This is also consistent with the purposes of FDA's Regional Small Business Program, which are in part to respond to industry inquiries, develop educational materials, sponsor workshops and conferences to provide firms, particularly small businesses, with firsthand working knowledge of FDA's requirements and compliance policies. This workshop is also consistent with the Small Business Regulatory Enforcement Fairness Act of 1996 (Public Law 104-121), as outreach activities by Government agencies to small businesses.

The goal of the workshop is to present information that will enable manufacturers and regulated industry to better comply with the Medical Device QSR. The following topics will be discussed at the workshop: (1) The production and process control subsystem of the QSR, (2) FDA 483 trends and applicable regulations, (3) the business friendly approach, (4) software validation, (5) process validation, (6) product acceptance including techniques and purchasing controls, and (7) device history records.

Dated: February 26, 2004.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. 04-4785 Filed 3-3-04; 8:45 am]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Institute on Drug Abuse; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDA.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute on Drug Abuse, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Board of Scientific Counselors, NIDA.

**Date:** May 12, 2004.

**Time:** 8:30 a.m. to 6 p.m.

**Agenda:** To review and evaluate personal qualifications and performance, and competence of individual investigators.

**Place:** Intramural Research Program, National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Bldg. C, 2nd Floor Auditorium, Baltimore, MD 21224.

**Contact Person:** Stephen J. Heishman, PhD, Research Psychologist, Clinical Pharmacology Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 5500 Nathan Shock Drive, Baltimore, MD 21224, (410) 550-1547.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS)

Dated: February 26, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-4795 Filed 3-3-04; 8:45 am]

**BILLING CODE 4140-01-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Institute on Drug Abuse; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

<sup>1</sup>FDA has verified the Web site address, but FDA is not responsible for subsequent changes to the Web site after this document publishes in the Federal Register.

amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel SBIR—Discovery of New Chemical Probes.”

*Date:* March 10, 2004.

*Time:* 1:30 p.m. to 5 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, Office of Extramural Affairs, NIDA, 6101 Executive Boulevard, Room 220, Rockville, MD 20852.

*Contact Person:* Eric Zatman, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892–8401, (301) 435–1438.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS)

Dated: February 26, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–4796 Filed 3–3–04; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Drug Abuse; Cancellation of Meeting

Notice is hereby given of the cancellation of the National Institute on Drug Abuse Special Emphasis Panel, March 10, 2004, 5 p.m. to March 10, 2004, 7 p.m. Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD, 20814 which was published in the **Federal Register** on February 19, 2004, Vol. 69, Num. 33.

The meeting is cancelled because the grant application was withdrawn.

Dated: February 26, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04–4797 Filed 3–3–04; 8:45 am]

**BILLING CODE 4140–01–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Zap 70 Protein Expression in Chronic Lymphocytic Leukemia (CLL)

**AGENCY:** National Institutes of Health, Public Health Services, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is a notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Provisional Patent Appl. Serial No. 60/375,966 (DHHS ref. no. E–091–2002/0–US–01) filed April 25, 2002, U.S. Patent Appl. Serial No. 10/309,548 (DHHS ref. no. E–091–2002/0–US–02), and Canadian Patent Application No. 2413475, all entitled “Zap 70 Expression as a Marker for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (CLL/ SLL),” to Cell Signaling Technology, Inc., of Beverly, Massachusetts. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory may be worldwide. The field of use may be limited to the use of antibody based products to diagnose chronic lymphocytic leukemia, wherein the antibody based products are regulated.

**DATES:** Only written comments and/or license applications which are received by the National Institutes of Health on or before May 3, 2004 will be considered.

**ADDRESSES:** Requests for copies of the patent(s)/patent application(s), inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Catherine M. Joyce, Intellectual Property Management Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone 301–435–5031; Facsimile 301–402–0220; E-mail [joycec@mail.nih.gov](mailto:joycec@mail.nih.gov).

**Technology Brief:** The above-referenced patent(s)/patent application(s) relate to the discovery that detection of Zap70 expression can be used to diagnose chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In particular, Zap70 expression can be used to distinguish between two subpopulations of CLL/SLL patients: (1) Patients who have stable or slowly progressing disease requiring late or no treatment or (2) patients who had progressive clinical course requiring early treatment.

**SUPPLEMENTARY INFORMATION:** The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 26, 2004.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 04–4798 Filed 3–3–04; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Notice of Request for Applications for Access to Recovery (ATR) Grants (TI 04–009)

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS

**ACTION:** Notice of request for applications for access to recovery (ATR) grants (TI 04–009).

**SUMMARY:** The United States Department of Health and Human Services (HHS), Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Treatment (CSAT) is accepting applications for